Skip to main content

Table 2 Amino acid substitutions, antifungal agent MICs, and patient’s characteristics for 22 Candida tropicalis clinical isolates

From: MDR1 overexpression combined with ERG11 mutations induce high-level fluconazole resistance in Candida tropicalis clinical isolates

Designation Origin Date of isolation Age /Sex Underlying disease Ward Substitution of amino acid residue (Erg11p) DST Antifungal agent MIC (mg/L) Previous azole usea Antifungal therapy Thirty-day outcome
FLU VOR ITR POS AMB 5FC
Ct01R Blood 8/5/15 37/M ALL Hematology Y132F, S154F 225 128 4 0.25 0.25 0.5 ≤0.06 FLU, VOR CAS, AMB Survival
Ct02R Pleural fluid 10/4/14 65/M Liver Transplantation ICU None 639 8 0.5 0.25 0.25 0.5 ≤0.06 VOR None Death
Ct03R Blood 9/12/13 72/F Chronic Renal Failure Gastroenterological Surgery Y132F, S154F 639 256 4 0.5 0.5 0.5 0.25 None FLU, AMB Death
Ct04R Blood 11/8/13 26/M ALL Hematology Y132F, S154F 329 64 2 0.25 0.25 0.5 ≤0.06 FLU ITR Survival
Ct05R Blood 2/22/15 40/M CML Hematology Y132F, S154F 615 128 4 0.25 0.5 0.5 0.12 FLU, ITR CAS Survival
Ct06R Blood 4/6/17 38/M AML Hematology Y132F, S154F NT 128 4 0.5 0.5 0.5 0.12 FLU, VOR CAS, AMB Survival
Ct07R Urine 9/15/14 87/F Cholangitis ICU Y132F, S154F 225 256 > 8 1 1 0.5 ≤0.06 None None Survival
Ct08R Urine 7/22/15 19/M Nephrlithotomy Urology Y132F, S154F 225 64 4 0.5 1 1 ≤0.06 None VOR Survival
Ct09R Urine 8/7/15 64/M Pneumonia Respiratory Y132F, S154F 225 > 256 8 1 1 1 ≤0.06 None None Survival
Ct10R Blood 9/2/15 25/F ALL Hematology Y132F, S154F 506 > 256 8 1 1 1 ≤0.06 ITR CAS Survival
Ct11R Urine 9/26/15 80/M Pneumonia ICU Y132F, S154F 508 64 2 0.25 0.25 0.5 ≤0.06 None None Death
Ct12R Urine 6/17/15 83/F Adrenocortical Carcinoma ICU Y132F, S154F 508 64 4 0.25 0.25 0.5 ≤0.06 None None Death
Ct01S Cervix 4/5/17 34/F Premature Delivery Obstetrics None NT 2 0.12 0.12 0.12 0.25 ≤0.06 None None Survival
Ct02S Sputum 6/15/17 62/M Respiratory Failure Respiratory None NT 1 0.12 0.12 0.12 0.25 ≤0.06 None None Survival
Ct03S Urine 6/23/17 16/F Ewing’s Sarcoma Musculoskeletal Tumor None NT 1 0.06 0.12 0.12 0.25 0.12 None FLU Survival
Ct04S Catheter 6/26/17 44/M Hepatocellular Carcinoma ICU None NT 2 0.12 0.25 0.25 0.25 ≤0.06 None None Death
Ct05S Blood 11/27/14 50/M Cirrhosis Hepatology None 519 2 0.12 0.25 0.25 1 ≤0.06 None CAS Survival
Ct06S Blood 2/13/15 43/M AML Hematology None 169 1 0.12 0.25 0.5 0.5 ≤0.06 None ITR Death
Ct07S Urine 7/3/15 80/M CHD Cardiology None 343 1 0.12 0.25 0.25 0.5 0.25 None None Survival
Ct08S Blood 9/25/15 42/M AML Hematology None 399 1 0.12 0.25 0.12 1 0.12 None VOR, AMB Death
Ct09S Blood 10/31/14 51/F AML Hematology None 300 2 0.25 0.25 0.25 0.5 0.12 None VOR, AMB Death
Ct10S Urine 7/26/17 23/M HPS ICU None 169 1 0.12 0.25 0.25 0.5 ≤0.06 None None Survival
  1. 5FC 5-flucytosine, ALL acute lymphocytic leukemia, AMB amphotericin B, AML acute myeloid leukemia, CAS caspofungin, CHD coronary heart disease, CML chronic myeloid leukemia, FLU fluconazole, HPS hemophagocytic syndrome, ITR itraconazole, NT untyped, POS posaconazole, VOR voriconazole
  2. awithin 3 months prior to the detection of C. tropicalis